Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Microfibril-associated glycoprotein-1, an extracellular matrix regulator of bone remodeling.

Craft CS, Zou W, Watkins M, Grimston S, Brodt MD, Broekelmann TJ, Weinbaum JS, Teitelbaum SL, Pierce RA, Civitelli R, Silva MJ, Mecham RP.

J Biol Chem. 2010 Jul 30;285(31):23858-67. doi: 10.1074/jbc.M110.113019. Epub 2010 May 25.

2.

Cellular and molecular mechanisms of bone remodeling.

Raggatt LJ, Partridge NC.

J Biol Chem. 2010 Aug 13;285(33):25103-8. doi: 10.1074/jbc.R109.041087. Epub 2010 May 25. Review.

3.

Osteopotentia regulates osteoblast maturation, bone formation, and skeletal integrity in mice.

Sohaskey ML, Jiang Y, Zhao JJ, Mohr A, Roemer F, Harland RM.

J Cell Biol. 2010 May 3;189(3):511-25. doi: 10.1083/jcb.201003006.

4.

Severe osteogenesis imperfecta in cyclophilin B-deficient mice.

Choi JW, Sutor SL, Lindquist L, Evans GL, Madden BJ, Bergen HR 3rd, Hefferan TE, Yaszemski MJ, Bram RJ.

PLoS Genet. 2009 Dec;5(12):e1000750. doi: 10.1371/journal.pgen.1000750. Epub 2009 Dec 4.

5.

Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation.

Murakami T, Saito A, Hino S, Kondo S, Kanemoto S, Chihara K, Sekiya H, Tsumagari K, Ochiai K, Yoshinaga K, Saitoh M, Nishimura R, Yoneda T, Kou I, Furuichi T, Ikegawa S, Ikawa M, Okabe M, Wanaka A, Imaizumi K.

Nat Cell Biol. 2009 Oct;11(10):1205-11. doi: 10.1038/ncb1963. Epub 2009 Sep 20.

PMID:
19767743
6.

Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling.

Ramirez F, Rifkin DB.

Curr Opin Cell Biol. 2009 Oct;21(5):616-22. doi: 10.1016/j.ceb.2009.05.005. Epub 2009 Jun 12. Review.

7.

Biogenesis and function of fibrillin assemblies.

Ramirez F, Sakai LY.

Cell Tissue Res. 2010 Jan;339(1):71-82. doi: 10.1007/s00441-009-0822-x. Epub 2009 Jun 10. Review.

8.

Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.

Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova-Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, Derynck R, Guise TA, Alliston T.

PLoS One. 2009;4(4):e5275. doi: 10.1371/journal.pone.0005275. Epub 2008 Apr 16.

9.

p38 MAPK is an early determinant of promiscuous Smad2/3 signaling in the aortas of fibrillin-1 (Fbn1)-null mice.

Carta L, Smaldone S, Zilberberg L, Loch D, Dietz HC, Rifkin DB, Ramirez F.

J Biol Chem. 2009 Feb 27;284(9):5630-6. doi: 10.1074/jbc.M806962200. Epub 2008 Dec 24.

10.

BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.

Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y.

Development. 2008 Nov;135(22):3801-11. doi: 10.1242/dev.025825. Epub 2008 Oct 16.

11.

Targeting of bone morphogenetic protein growth factor complexes to fibrillin.

Sengle G, Charbonneau NL, Ono RN, Sasaki T, Alvarez J, Keene DR, B├Ąchinger HP, Sakai LY.

J Biol Chem. 2008 May 16;283(20):13874-88. doi: 10.1074/jbc.M707820200. Epub 2008 Mar 13.

12.

Marfan syndrome: from molecular pathogenesis to clinical treatment.

Ramirez F, Dietz HC.

Curr Opin Genet Dev. 2007 Jun;17(3):252-8. Epub 2007 Apr 27. Review. Erratum in: Curr Opin Genet Dev. 2007 Aug;17(4):367.

PMID:
17467262
13.

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.

Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC.

Nat Med. 2007 Feb;13(2):204-10. Epub 2007 Jan 21. Erratum in: Nat Med. 2007 Apr;13(4):511.

14.

CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta.

Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, Castagnola P, Rauch F, Glorieux FH, Vranka J, B├Ąchinger HP, Pace JM, Schwarze U, Byers PH, Weis M, Fernandes RJ, Eyre DR, Yao Z, Boyce BF, Lee B.

Cell. 2006 Oct 20;127(2):291-304.

15.

Fibrillins: from biogenesis of microfibrils to signaling functions.

Hubmacher D, Tiedemann K, Reinhardt DP.

Curr Top Dev Biol. 2006;75:93-123. Review.

PMID:
16984811
16.

Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.

Okamoto M, Murai J, Yoshikawa H, Tsumaki N.

J Bone Miner Res. 2006 Jul;21(7):1022-33.

17.

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC.

Science. 2006 Apr 7;312(5770):117-21.

18.

Fibrillins 1 and 2 perform partially overlapping functions during aortic development.

Carta L, Pereira L, Arteaga-Solis E, Lee-Arteaga SY, Lenart B, Starcher B, Merkel CA, Sukoyan M, Kerkis A, Hazeki N, Keene DR, Sakai LY, Ramirez F.

J Biol Chem. 2006 Mar 24;281(12):8016-23. Epub 2005 Dec 28.

19.

p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling.

Wang X, Kua HY, Hu Y, Guo K, Zeng Q, Wu Q, Ng HH, Karsenty G, de Crombrugghe B, Yeh J, Li B.

J Cell Biol. 2006 Jan 2;172(1):115-25. Epub 2005 Dec 27.

20.

Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts.

Bi Y, Nielsen KL, Kilts TM, Yoon A, A Karsdal M, Wimer HF, Greenfield EM, Heegaard AM, Young MF.

Bone. 2006 Jun;38(6):778-86. Epub 2005 Dec 20.

PMID:
16364709

Supplemental Content

Support Center